RBC Capital Positive on Valeant's (VRX) CFO Hire

August 22, 2016 8:25 AM EDT
Get Alerts VRX Hot Sheet
Price: $15.63 --0%

Rating Summary:
    11 Buy, 11 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 4
Trade VRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst Douglas Miehm views Valeant Pharmaceuticals' (NYSE: VRX) hiring of Paul Herendeen as EVP and CFO as a positive.

Miehm notes from Herendeen comes from Zoetisc and has over 16 years of public company CFO experience.

"We view the addition positively and note that Mr. Herendeen's experience in various CFO roles should strengthen Valeant's executive team," the analyst said.

The firm retained their Sector Perform rating and price target of $36 on VRX.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $28.74 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital

Add Your Comment